Notice: file_put_contents(): Write of 8078 bytes failed with errno=28 No space left on device in /var/www/tg-me/post.php on line 50
Readhub | Telegram Webview: readhub_cn/247128 -
Telegram Group & Telegram Channel
阿斯利康PD-L1肿瘤药在中国获批第四项适应证

阿斯利康的PD-L1肿瘤药物度伐利尤单抗(英飞凡)在中国获得第四项适应证批准,用于联合含铂化疗作为新辅助治疗,术后继续单药辅助治疗可手术切除的Ⅱ、ⅢA和ⅢB期非小细胞肺癌患者。度伐利尤单抗是一种人源化PD-L1单克隆抗体,2024年全球收入达47.17亿美元,同比增长21%。

媒体报道
阿斯利康PD-L1肿瘤药在中国获批第四项适应证 华尔街见闻/钛媒体/格隆汇/财联社

事件追踪
2025-02-26 阿斯利康TSLP单抗申报新适应症,治疗慢性鼻-鼻窦炎伴鼻息肉
2024-08-16 美国FDA批准阿斯利康重磅药物Imfinzi用于治疗非小细胞肺癌
2020-07-27 阿斯利康与日本第一三共达成60亿美元肿瘤药合作协议

#热门话题



tg-me.com/readhub_cn/247128
Create:
Last Update:

阿斯利康PD-L1肿瘤药在中国获批第四项适应证

阿斯利康的PD-L1肿瘤药物度伐利尤单抗(英飞凡)在中国获得第四项适应证批准,用于联合含铂化疗作为新辅助治疗,术后继续单药辅助治疗可手术切除的Ⅱ、ⅢA和ⅢB期非小细胞肺癌患者。度伐利尤单抗是一种人源化PD-L1单克隆抗体,2024年全球收入达47.17亿美元,同比增长21%。

媒体报道
阿斯利康PD-L1肿瘤药在中国获批第四项适应证 华尔街见闻/钛媒体/格隆汇/财联社

事件追踪
2025-02-26 阿斯利康TSLP单抗申报新适应症,治疗慢性鼻-鼻窦炎伴鼻息肉
2024-08-16 美国FDA批准阿斯利康重磅药物Imfinzi用于治疗非小细胞肺癌
2020-07-27 阿斯利康与日本第一三共达成60亿美元肿瘤药合作协议

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/247128

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

Launched in 2013, Telegram allows users to broadcast messages to a following via “channels”, or create public and private groups that are simple for others to access. Users can also send and receive large data files, including text and zip files, directly via the app.The platform said it has more than 500m active users, and topped 1bn downloads in August, according to data from SensorTower.

Importantly, that investor viewpoint is not new. It cycles in when conditions are right (and vice versa). It also brings the ineffective warnings of an overpriced market with it.Looking toward a good 2022 stock market, there is no apparent reason to expect these issues to change.

Readhub from hk


Telegram Readhub
FROM USA